Clinical Trial Update: Study of the Pharmacokinetics and Safety of Recombinant Factor VIIa Fusion Protein (rVIIa-FP, CSL689) in Patients With Congenital Factor VII Deficiency [Phase 1]

View source ↗

Summary

This Phase 1 clinical trial evaluated the pharmacokinetics and safety of recombinant Factor VIIa fusion protein CSL689 (rVIIa-FP) in patients with congenital Fa…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Congenital Factor Vii Deficiency

Drugs mentioned

• rVIIa-FP (CSL689) (recombinant Factor VIIa fusion protein)

Snippet

Sponsor: CSL Behring | Conditions: Congenital Coagulation Factor VII Deficiency | Phase 1 | Status: COMPLETED